Journals / Eurasian Journal of Medicine / 2021 / Cilt: 53 - Sayı: 2

What Has Changed in the Treatment of Psoriatic Arthritis After COVID-19?

Pages
132–136
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, webriefly address the management options and treatment recommendations for patients with psoriatic arthritisduring and after the coronavirus disease 2019 pandemic in light of recent scientific publications.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Coronavirus disease 2019 is a respiratory infection caused by severe acute respiratory syndrome coronavirus2.
📊
Key Findings & Data:Coronavirus disease 2019 leads to the rapid activation of innate immune cells, particularly in patients withsevere disease.
💡
Conclusion & Impact:In this review, webriefly address the management options and treatment recommendations for patients with psoriatic arthritisduring and after the coronavirus disease 2019 pandemic in light of recent scientific publications.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Coronavirus disease 2019 is a respiratory infection caused by severe acute respiratory syndrome coronavirus2. Coronavirus disease 2019 leads to the rapid activation of innate immune cells, particularly in patients withsevere disease. Psoriatic arthritis is a heterogeneous chronic inflammatory disease characterized by the association of psoriasis and arthritis. Similar to those with other viruses, patients with psoriatic arthritis are ata significant risk of infection with severe acute respiratory syndrome coronavirus 2. Patients with psoriaticarthritis are immunosuppressed owing to immune dysregulation during the active disease period or owing toimmunosuppressive drugs administered during remission, and they are prone to infections. The severe acuterespiratory syndrome coronavirus 2 is a threat to millions of people globally owing to the decline in immunityand because a significant number of people develop severe illness. In the period of coronavirus disease 2019pandemic, we briefly present recommendations for the treatment of psoriatic arthritis. In this review, webriefly address the management options and treatment recommendations for patients with psoriatic arthritisduring and after the coronavirus disease 2019 pandemic in light of recent scientific publications.

🔖

Cite This Article

Keskin, Y., Nas, K., Koz, G. (2022). What Has Changed in the Treatment of Psoriatic Arthritis After COVID-19?. Eurasian Journal of Medicine, Cilt: 53 - Sayı: 2, 132–136. https://ajindex.com/articles/508823

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. [Crossref] 2. Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. 2020;39(7):2055- 2062. [Crossref] 3. Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol. 2020;215:108448. [Crossref] 4. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-269. [Crossref] 5. Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20(5):271- 272. [Crossref] 6. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalised patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama. 2020;323(11): 1061-1069. [Crossref] 7. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497- 506. [Crossref] 8. Megna M, Napolitano M, Patruno C, Fabbrocini G. Biologics for psoriasis in COVID-19 era: what do we know? Dermatol Ther. 2020;33(4):e13467. [Crossref] 9. Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130(5): 2202-2205. [Crossref] 10. Coletto LA, Favalli EG, Caporali R. Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID-19days. Dermatol Ther. 2020;33(4):e13415. [Crossref] 11. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: faraway, so close! Autoimmun Rev. 2020;19(5):102523. [Crossref] 12. Liu Y, Chang C, Lu Q. Management strategies for patients with autoimmune diseases during the COVID-19 pandemic: a perspective from China. Eur J Rheumatol 2020;(Suppl 2):S94-S96. [Crossref] 13. Messina F, Piaserico S. SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor. J Eur Acad Dermatol Venereol. 2020;34(6):e254-e255. [Crossref] 14. Di Lernia V, Bombonato C, Motolese A. COVID19 in an elderly patient treated with secukinumab. Dermatol Ther. 2020;33(4):e13580. [Crossref] 15. Haberman R, Axelrad J, Chen A, et al. Covid19 in immune-mediated inflammatory diseases - case series from New York. N Engl J Med. 2020;383(1):85-88. [Crossref] 16. Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ. 2020;368:m11